Dr. Borgman joins the board with over two decades of clinical development experience, focusing on oncology and hematology therapeutics. She most recently served as vice president and global therapeutic area lead, hematology-oncology, for Jazz Pharmaceuticals.
Dr. Borgman also served as vice president of clinical research and development at Exelixis and chief medical officer at Hana Biosciences. She is currently on the board of directors for Curis and NextCure, according to a Jan. 18 release from NiKang.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
